Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today reported data demonstrating that Hodgkin lymphoma patients at risk of relapse following an autologous stem cell transplant who received ADCETRIS as consolidation therapy immediately after ASCT had significant improvement in progression-free survival compared to patients who received placebo . The data from the AETHERA trial were featured at the 56th American Society of Hematology Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
http://ift.tt/1ADtg0v
http://ift.tt/1ADtg0v
No comments:
Post a Comment